Hackensack Researchers Present Transformative Studies at Annual Cancer Meeting   

Hackensack Researchers Present Transformative Studies at Annual Cancer Meeting

Presentations and publications focus on immunotherapy, cellular therapy, targeted therapy, and biomarker research for solid tumors and hematologic cancers

Researchers from Hackensack Meridian John Theurer Cancer Center (JTCC)—a research partner with Georgetown’s  Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center.  —and Hackensack University Medical Center are reporting transformative results from 35 studies at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest gathering of cancer professionals. The meeting was held May 31 through June 4 in Chicago.

Several of the studies focus on optimizing the use of immune-boosting and targeted therapies in combination with investigational or standard treatments for solid tumors such as those of the pancreas, kidney, lung, liver, breast, brain, colon/rectum, and ovaries. Others highlight advances in the use of stem cell transplantation and other approaches to treat blood cancer such as multiple myeloma, leukemia, and lymphoma. Investigators are also presenting data on RNA-based technologies to monitor treatment response in people with cancer.

Immunotherapy and other novel treatments for solid tumors

Hematologic cancer management

Cellular therapies

RNA and biomarker studies

Pediatric cancers

We use cookies to improve your experience. Please read our Privacy Policy or click Accept.
X